Eisai, Astellas Experience Delays In Seeking U.S. Drug Approvals
This article was originally published in PharmAsia News
Executive Summary
Eisai and Astellas Pharma separately announced delays in seeking U.S. approval for new drugs, Eisai for more than a year. Eisai said the decision to put off applying for its E7389 (eribulin mesylate) cancer drug would affect the company's long-term business goals. But President Haruo Naito added the company expects to garner more sales at the beginning of its eventual marketing effort as a result. Astellas said it would delay filing for a new formulation of its Prograf (tacrolimus) as a liver transplant immunosuppressant by three months because the U.S. FDA said it needed that time to review the application. (Click here for more
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.